Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
Relay Therapeutics, a clinical-stage precision medicine company, has announced that registration is now open for its virtual analyst and investor event scheduled for June 27, 2022. The event will run from 8:00 a.m. to 9:00 a.m. ET and will be accessible via the company’s website. Relay Therapeutics aims to innovate drug discovery through its advanced Dynamo™ platform, targeting oncology and genetic diseases. The company focuses on developing transformative therapies utilizing unique computational and experimental technologies.
- Registration is open for a virtual analyst and investor event, which can enhance investor engagement.
- The company is leveraging its Dynamo™ platform for innovative drug discovery in oncology and genetic diseases.
- None.
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is open for the virtual analyst and investor event on June 27, 2022 from 8:00 a.m. to 9:00 a.m. ET.
The virtual analyst and investor event will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of disparate technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
What is Relay Therapeutics' stock symbol?
When is the Relay Therapeutics virtual analyst and investor event?
How can I access the Relay Therapeutics investor event?
What technology does Relay Therapeutics use for drug discovery?
